Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Clinical Study to Evaluate the Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor

NCT01684098 is registered in ClinicalTrials.gov with Endocyte as lead sponsor.

NCT NCT01684098
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01684098 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Clinical Study to Evaluate the Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor
Lead sponsor
Endocyte
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2003
Completion date
August 31, 2005
Enrollment
40
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, head and neck cancer, pancreas cancer, recurrent or metastatic cancer, testicular cancer